Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486406 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
A Phase 2 study of Chronic Hepatitis C Infection, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT02486406: Completed Phase 2 study of Chronic Hepatitis C Infection, sponsored by AbbVie.
NCT02486406 is a Phase 2 study of Chronic Hepatitis C Infection that has completed, run by AbbVie. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02486406, a Phase 2 study of Chronic Hepatitis C Infection, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.
Primary Outcome
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG Ombitasvir/paritaprevir/ritonavir
- DRUG Dasabuvir
- DRUG Ombitasvir mini tablet
- DRUG Paritaprevir mini tablet
Study Locations (20)
Other
- UZ Leuven /ID# 136911 - Leuven
- Charite Universitaetsmedizin Berlin /ID# 141620 - Berlin
- Universitaetsklinikum Freiburg /ID# 141618 - Freiburg im Breisgau
- Helios Klinikum Wuppertal /ID# 142883 - Wuppertal
- San Jorge Children Hospital /ID# 136832 - San Juan
- Hospital Universitario Vall d'Hebron /ID# 137098 - Barcelona
- Hospital Universitario La Paz /ID# 137094 - Madrid
Florida
- University of Florida - Archer /ID# 136830 - Gainesville
- Advent Health /ID# 167663 - Orlando
Massachusetts
- Boston Childrens Hospital /ID# 137174 - Boston
- Boston Medical Center /ID# 136831 - Boston
California
- UCSF Benioff Childrens Hosp /ID# 136774 - San Francisco
Colorado
- Children's Hospital Colorado /ID# 137017 - Aurora
Indiana
- Indiana University /ID# 137015 - Indianapolis
New York
- Columbia Univ Medical Center /ID# 136431 - New York
Pennsylvania
- Children's Hospital of Philadelphia /ID# 137018 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
What the finished NCT02486406 record still lists
NCT02486406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Chronic Hepatitis C Infection appearing as the primary indexed condition, and to 5 interventions - of which Ribavirin is the first listed.
NCT02486406 names 20 study sites across 12 states, led by Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02486406 about?
NCT02486406 is a clinical study titled "A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects". This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pedi...
What is the current status of trial NCT02486406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-10-28. Estimated completion is 2020-11-19.
What conditions does trial NCT02486406 study?
This clinical trial studies the following conditions: Chronic Hepatitis C Infection.
What interventions are being tested in trial NCT02486406?
The interventions under investigation include: Ribavirin (DRUG), Ombitasvir/paritaprevir/ritonavir (DRUG), Dasabuvir (DRUG), Ombitasvir mini tablet (DRUG), Paritaprevir mini tablet (DRUG).
Who is sponsoring clinical trial NCT02486406?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02486406 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02486406's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI